<DOC>
	<DOC>NCT01909908</DOC>
	<brief_summary>The Extracellular Matrix (ECM) and Blood Components for Wound Healing feasibility study is a clinical trial approved by Health Canada to study the safety of extracellular matrix (ECM) and autologous blood products in wound healing.</brief_summary>
	<brief_title>ECM and Blood Components for Wound Healing</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>Type 1 or Type 2 diabetes, and/or venous insufficiency to the affected leg Ulcer has been present between 12 and 52 weeks Ulcer is less than 40 cm2 in area Less than 18 years of age Pregnant or planning to become pregnant during the study period Simultaneously participating in another investigational drug or device study Unable or unwilling to comply with the weekly study followup schedule or offloading regimen Patient or legal representative refuses to sign the ECapproved informed consent form Known allergy to pig or porcine products Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Wounds and injuries</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Diabetic angiopathies</keyword>
	<keyword>Diabetic foot</keyword>
	<keyword>Venous insufficiency</keyword>
	<keyword>Extracellular matrix</keyword>
</DOC>